Source:http://linkedlifedata.com/resource/umls/id/C0663182
NCI: A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).,PDQ: A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42006&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42006&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1569" NCI Thesaurus),NCI: A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the